Ultragenyx Pharmaceutical Inc (RARE)

Apr 02, 2025

How another firm's FDA approval could mean a big win for Denali Therapeutics - The Business Journals

Apr 02, 2025

Apr 02, 2025

Winners and wishers: 9 potential Bay Area drug approvals coming this year - The Business Journals

Apr 02, 2025

Apr 02, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week LowShould You Sell? - MarketBeat

Apr 02, 2025

Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025

Mar 29, 2025

Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey

Mar 29, 2025

Mar 27, 2025

Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning - Benzinga

Mar 27, 2025

Mar 27, 2025

Ultragenyx price target raised to $117 from $104 at JPMorgan - TipRanks

Mar 27, 2025

Mar 26, 2025

Ultragenyx stock hits 52-week low at $36.99 amid market challenges - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

Ultragenyx stock hits 52-week low at $36.99 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 24, 2025

Ultragenyx CEO Emil Kakkis: ‘Our Future Is In Our Hands’ - insights.citeline.com

Mar 24, 2025

Mar 24, 2025

Can UX111 Script History As The First FDA-Approved Treatment For Sanfilippo Syndrome Type A? - RTTNews

Mar 24, 2025

Mar 19, 2025

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN

Mar 19, 2025

Mar 19, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mar 19, 2025

Mar 19, 2025

Ultragenyx Strengthens Team with Strategic RSU Grants Worth Millions - StockTitan

Mar 19, 2025

Mar 18, 2025

Ultragenyx price target lowered to $115 from $140 at Piper Sandler - Yahoo Finance

Mar 18, 2025

Mar 17, 2025

Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight By Investing.com - Investing.com Canada

Mar 17, 2025

Mar 17, 2025

Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews - Benzinga

Mar 17, 2025

Mar 17, 2025

Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight - Investing.com

Mar 17, 2025

Mar 17, 2025

Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace

Mar 17, 2025

Mar 12, 2025

Trending Report on X-linked Hypophosphatemia Market 2025-2032 - openPR

Mar 12, 2025

Mar 11, 2025

Have Insiders Sold Ultragenyx Pharmaceutical Shares Recently? - Simply Wall St

Mar 11, 2025

Mar 10, 2025

Ultragenyx pharmaceutical CFO sells $72,114 in common stock By Investing.com - Investing.com Canada

Mar 10, 2025

Mar 10, 2025

Ultragenyx pharmaceutical CFO sells $72,114 in common stock - Investing.com India

Mar 10, 2025

Mar 07, 2025

Ultragenyx Pharmaceutical, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 07, 2025

Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Growth Potential and Robust Pipeline - TipRanks

Mar 07, 2025

Mar 06, 2025

FDA grants priority review to gene therapy for Sanfilippo type A - Sanfilippo News

Mar 06, 2025

Mar 05, 2025

Ultragenyx Pharmaceutical Inc Reports Q4 2024 Revenue of $165 Mi - GuruFocus.com

Mar 05, 2025

Mar 05, 2025

Ultragenyx pharmaceutical CBO Kassberg sells $253k in stock By Investing.com - Investing.com Australia

Mar 05, 2025

Mar 05, 2025

Ultragenyx’s chief accounting officer sells $40,710 in stock By Investing.com - Investing.com Australia

Mar 05, 2025

Mar 05, 2025

Ultragenyx pharmaceutical executive sells $607,881 in stock By Investing.com - Investing.com Australia

Mar 05, 2025

Mar 04, 2025

Ultragenyx pharmaceutical CBO Kassberg sells $253k in stock - Investing.com India

Mar 04, 2025

Mar 04, 2025

Ultragenyx EVP Eric Crombez sells $376,584 in stock - Investing.com India

Mar 04, 2025

Mar 04, 2025

Ultragenyx EVP Eric Crombez sells $376,584 in stock By Investing.com - Investing.com Australia

Mar 04, 2025

Mar 04, 2025

Ultragenyx pharmaceutical EVP sells $635,836 in stock - Investing.com India

Mar 04, 2025

Mar 04, 2025

Ultragenyx pharmaceutical EVP sells $635,836 in stock By Investing.com - Investing.com Canada

Mar 04, 2025

Mar 04, 2025

Ultragenyx pharmaceutical executive sells $607,881 in stock - Investing.com

Mar 04, 2025

Mar 04, 2025

Ultragenyx CEO Emil Kakkis sells $4.15 million in stock By Investing.com - Investing.com UK

Mar 04, 2025

Mar 04, 2025

Ultragenyx’s chief accounting officer sells $40,710 in stock - Investing.com

Mar 04, 2025

Mar 04, 2025

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.

Mar 04, 2025

Mar 04, 2025

Ultragenyx EVP Karah Parschauer sells $128,223 in stock By Investing.com - Investing.com Canada

Mar 04, 2025

Mar 03, 2025

Ultragenyx Loses Bid To Toss Suit Over Henrietta Lacks' Cells - Law360

Mar 03, 2025

Mar 03, 2025

Ultragenyx EVP Karah Parschauer sells $128,223 in stock - Investing.com India

Mar 03, 2025

Mar 01, 2025

(RARE) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 01, 2025

Mar 01, 2025

Y Intercept Hong Kong Ltd Raises Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Mar 01, 2025

Mar 01, 2025

Ultragenyx Pharmaceutical’s (RARE) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World

Mar 01, 2025